Shed Review: It Quotes the Placebo Arm, Then Sells a Peptide With No Trial

The longevity range, where the care runs out

Shed's longevity line is Microdose GLP-1, glutathione, methylene blue, NAD+, low-dose naltrexone and sermorelin.

Sermorelin is $199 a month, taken five times weekly. Shed describes it well:

"Sermorelin is a growth hormone-releasing hormone (GHRH) analog that stimulates the pituitary gland to naturally produce more growth hormone… Unlike synthetic GH injections, which introduce GH directly, Sermorelin works with the body's natural feedback mechanisms."

All true. And it publishes real clinical detail almost nobody else does: a dose range of 100–300 micrograms, subcutaneous administration at night to align with the body's growth-hormone cycle, and a contraindication list naming active cancer, pituitary disorders, pregnancy and breastfeeding, and diabetes or insulin resistance.

Then this:

"it appeals to those seeking a safer, more natural alternative to synthetic growth hormone therapy, particularly for its potential anti-aging and metabolic benefits."

Safer is a comparative clinical claim. No trial has compared sermorelin with growth hormone for safety — the 19 that exist ran between 1986 and 2005 and measured growth-hormone output, not harm.

A ClinicalTrials.gov search returns no interventional record naming sermorelin as the intervention — searched six ways, including "sermorelin acetate", "GHRH(1-29)" and "Geref", its withdrawn US brand name, plus a free-text pass over every field. ¹ The 27 studies returned are other molecules — mostly tesamorelin and GHRH(1-44). PubMed holds 24 mentions and zero with a randomized-trial publication type. ² The same searches find trials when they exist: 158 registry records for tirzepatide, 17 for tesamorelin, 10 for bremelanotide.

Shed hedges it — "appeals to those seeking", "potential" benefits — which is why this reads as a claim reaching past its evidence rather than a fabrication. It is still the one sentence on the page a buyer should not rely on.

Where Shed gets NAD+ right

Its NAD+ line, from $144 a month, is offered as an injection, a tablet or a nasal spray, with the route presented as the provider's decision.

The copy is careful in three specific ways. It calls NAD+ "a coenzyme found naturally in the body" — correct, where a competitor in this wave heads its NAD+ page "a peptide that signals your own pituitary gland". It says levels change with age "which has been linked to fatigue, cognitive slowdown, and metabolic inefficiencies" — a correlation described as a correlation rather than as a mechanism of action.

And asked the question every buyer asks, it declines to answer:

"When will I start to notice changes? Responses vary for everyone. Some people notice changes early on, while some may not notice significant changes."

Two competitors in this series publish month-by-month schedules of expected results for peptides with no trials at all. Telling a prospective customer they might notice nothing is the opposite of that.

What Shed does not say is that there is no completed human trial of injected or intranasal NAD+ at all, and that the substantial human literature is about oral precursors — nicotinamide riboside and nicotinamide mononucleotide — which are different molecules taken a different way. ³

The right population, the wrong route

Shed's sex-health range lists, under For Women:

"Desire Rx — Sublingual tablet · libido support (Oxytocin / Bremelanotide)"

Putting bremelanotide in a women's line is correct and unusual. Its two phase 3 trials, RECONNECT 1 and 2, enrolled 723 and 714 premenopausal women with hypoactive sexual desire disorder, and the approved product's label carries Limitations of Use excluding men and performance enhancement. ^{5 6} Three other sellers in this series put the same molecule in a men's performance line.

Two things still do not match the trials. The approved product is a subcutaneous autoinjector; Shed's is a sublingual tablet, and no registered trial tested bremelanotide by that route. And it is combined with oxytocin, for which no trial of the combination exists.

Who makes it

Nobody named. Shed says its medications are "made by a licensed pharmacy based on a provider's prescription" — honest as far as it goes, and it goes no further. No pharmacy name, no address, no phone number.

That matters practically. There is no certificate of analysis, lot number, potency or sterility result published for any product — which is true of every company we've reviewed — but here there is also nobody to ask, because the party holding those records is never identified.

No prescribing clinician is named either, and no medical group is identified.

On coverage Shed is better than its peers, and the evidence is data rather than a slogan: its own signup portal carries a 52-entry state table — all fifty states, the District of Columbia and Puerto Rico — and the accompanying disqualified-states list is empty. There is no jurisdiction the portal turns away.

What this means if you are buying

For a GLP-1, Shed is one of the better-documented options we've reviewed. The figures it shows you are real, the placebo comparison is right there, and the compounded disclaimer is attached to the claim rather than hidden.

On price, expect to pay more than the banner. Walking the intake on 26 August 2026 with dummy answers reached the treatment screen, and every compounded figure on it is a starting price — the same "from" numbers the homepage advertises, with no plan length attached. The options that turn those into a monthly cost appear after you press continue to checkout, which is where Shed asks you to create an account. We did not create one, so we cannot tell you what the plan lengths cost today.

What we can tell you is what was recorded before. On 10 August 2026 this network's cost review put the walk-away price at $199 a month for semaglutide and $299 for tirzepatide. Those are dated readings, not current quotes, and they are roughly a quarter above the advertised "from" prices. Treat them as the shape of the gap rather than the size of your bill, budget above the banner, and read the terms on the 120-day guarantee before relying on it.

For sermorelin, know that the careful clinical detail on the page — the dose range, the timing, the contraindications — sits on top of a molecule with no human trial under any name, and that "safer than growth hormone" is a comparison nobody has run.

For NAD+, the page is honest about what it does not know. It just does not tell you that the evidence which exists is for a different molecule taken a different way.

And for anything here: ask which pharmacy is making it, because the website will not tell you.